Proliferation of mesenchymal stem cell trials for COVID-19: risks and recommendations

Smith JA., Abhari RE., Collins G., Carr AJ.

<p>At least 20 clinical trials of mesenchymal stem/stromal cells (MSCs) for the treatment of covid-19 have been registered. We assess the emerging trial registrations and argue that the information gain is likely to be low, while the likelihood of false-positives and over-interpretation is high. The rush to test treatments may come at the expense of research quality.</p>

DOI

10.31222/osf.io/72j6z

Type

Journal article

Journal

Open science framework

Publisher

Center for Open Science

Publication Date

27/10/2020

Permalink Original publication